Disitamab Vedotin has been granted breakthrough designations in the United States and China, new drug application (NDA) of urothelial carcinoma was accepted

2021-07-15

The first time in China! Two indications of Disitamab Vedotin have been granted breakthrough designations in the United States and China for three times

2021-06-30

Disitamab Vedotin has become the first ADC drug created and developed by a China biopharma to receive marketing approval!

2021-06-10

荣昌生物房健民:做特立独行的ADC,找准适应症不扎堆

2020-04-04

泰它西普:全球原创新药从烟台走向世界

2020-03-09

【山东新闻联播】荣昌生物:新药产业化撬动生物医药产业集群

2019-11-29
1 / 1
Twitter Facebook 微博

Company Wechat

© All Right Reserved .  ICP:鲁ICP备11031710号-1